We specialize in metabolic and cardiovascular disorders, women’s health, and clinical trials involving renal and hepatic impaired patients. Leveraging our deep knowledge, we provide expert guidance to navigate the complexities of drug development.
Our extensive expertise makes us an ideal partner for biopharmaceutical companies, offering strategic and tactical project-related outsourcing partnerships.
CRS was established in 2006 through the merger of three renowned CROs in Germany:
These organizations brought together over 40 years of collective experience in clinical pharmacology and Phase I clinical trials. Today, CRS operates three Clinical Pharmacology Units (CPUs) across Germany, with a combined capacity of more than 160 beds. This infrastructure positions us as one of Europe’s leading providers of Phase I clinical trial services, offering both standard PharmacoKinetic (PK) / PharmacoDynamic (PD) trial designs and specialized Phase I studies.
Our clients span pharmaceuticals, biotech, medicinal products, nutritional, and cosmetics industries. CRS delivers a comprehensive suite of services, including early phase clinical trials in healthy volunteers, patient-driven trials, and multicenter trials.
Partner with us to benefit from our proven track record and commitment to excellence in early phase drug development strategies.